Rabbit Anti-Ebola Virus VP40 Protein Antibody, 1F2
$350.00 – $1,500.00
|Product Name||Rabbit Anti-Ebola Virus VP40 Protein Antibody, 1F2|
|Preparation||Recombinant monoclonal antibody expressed in HEK293F cells and purified by protein A affinity chromatography.|
|Applications||ELISA, Indirect Immunofluorescence Assay, Lateral Flow|
|Reactivity||Sudan, Mayinga, Bundibugyo and Tai Forest|
|Isotype||rabbit IgG, kappa|
|Storage conditions||For long term storage, the antibody should be stored at -20℃ and is stable for 12 months from
the date of receipt. Avoid repeated freeze-thaw cycles. For short term storage, keep at 4oC for a week should be fine.
|Application Dilution||1:1,000-1:100,000 (platform dependent, customers must test the optimal concentration on their own platform)|
Ebola virus disease (EVD) is a severe disease caused by Ebola virus, a member of the filovirus family, which occurs in humans and other primates. The disease was identified in 1976, in almost simultaneous outbreaks in the Democratic Republic of the Congo (DRC) and Sudan.
Until 2014, outbreaks of EVD were primarily reported from remote villages close to tropical rainforests in Central and West Africa. Most confirmed cases were reported from the DRC, Gabon, the Republic of the Congo, Sudan and Uganda. In 2014, an EVD outbreak was reported for the first time in West Africa (Guinea, Liberia and Sierra Leone). During this outbreak, which was ongoing between 2014 and 2016, there was intense transmission in urban areas, resulting in over 28,000 reported cases. Multiple countries including Italy, Mali, Nigeria, Senegal, Spain, the UK and the US, reported imported EVD cases associated with this outbreak (see section 1.3 below).
There are 6 species of Ebola virus, 4 of which are known to cause disease in humans:
Zaire ebolavirus (EBOV)
Sudan ebolavirus (SUDV)
Tai Forest ebolavirus (TAFV) (formerly known as Ebola Ivory Coast)
Bundibugyo ebolavirus (BDBV)
EVD is a key to charting a path towards stronger resilience against the disease. There have been remarkable shifts in diagnostics, at risk populations, impact on health systems and response approaches. The health sector continues to gain global experiences about EVD which has shaped preparedness, prevention, detection, diagnostics, response, and recovery strategies.